Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?
Both drugs work. But tirzepatide averages 20–22% weight loss vs 15% for semaglutide — and costs significantly more. Here's how doctors in India decide which to prescribe.
Dr. Vikram Sharma
ALTRcare Medical Team
Understanding GLP-1 Medications
The two most prescribed GLP-1 medications in India are semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). While both are effective for weight loss, they work slightly differently and have distinct advantages.
Semaglutide: The Proven Standard
Semaglutide has been around longer and has extensive clinical data. It's a GLP-1 receptor agonist that slows gastric emptying and increases satiety signals in your brain.
- Average weight loss: 15% of body weight over 6 months
- Cost in India: ₹6,500–8,000 per month
- Mechanism: Single-action (GLP-1 only)
- Best for: First-time GLP-1 users, BMI 27–32
Tirzepatide: The Stronger Option
Tirzepatide is newer and works on two receptors instead of one. This dual mechanism produces stronger results.
- Average weight loss: 20–22% of body weight over 6 months
- Cost in India: ₹15,000–20,000 per month
- Mechanism: Dual-action (GLP-1 + GIP)
- Best for: BMI 30+, faster results needed
How Your Doctor Decides
The choice depends on:
- Your BMI: Higher BMI = stronger medication warranted
- Waist circumference: Above 90 cm (men) or 80 cm (women) favors tirzepatide
- Budget: Semaglutide is more affordable for long-term treatment
- Health conditions: Insulin resistance or pre-diabetes may favor tirzepatide
The Bottom Line
Both medications are safe and effective when prescribed by a doctor. Most patients start on semaglutide, then switch to tirzepatide after 3–6 months if results plateau. Your ALTRcare doctor will recommend the best option based on your bloodwork and goals.
Ready to take action?
Start your personalized weight loss plan with a free doctor consultation.